Repaglinide product-specific bioequivalence guidance
HumanScientific guidelines
This document provides product-specific guidance on the demonstration of the bioequivalence of repaglinide. Please note that no comments have been received for this guideline during the public consultation period.
Keywords:Â Bioequivalence, generics, repaglinide
Abbreviations:
Repaglinide tablets 0.5, 1 and 2 mg product-specific bioequivalence guidance
Draft repaglinide product-specific bioequivalence guidance